Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
7
×
life sciences
national blog main
san francisco blog main
7
×
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
eli lilly
fda
amgen
bristol-myers squibb
fremanezumab
merck
novartis
teva pharmaceutical
alder biopharmaceuticals
allergan
blueprint medicines
What
drug
7
×
new
7
×
approval
companies
fda
approved
bio
cancer
class
medicine
medicines
migraine
nash
roundup
targets
won
advantages
amgen
arguments
bar
big
biogen’s
biopharmaceutical
biotech
black
brings
candidates
clinic
commercialized
competitors
convo
data
decades
deeper
developed
diamond
disease
dna
drugs
earlier
Language
unset
Current search:
drug
×
new
×
" san francisco blog main "
×
" clinical trials "
×
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines